Adenosine 2B receptor antagonism alleviates liver fibrosis progression and induces mild fibrosis regression

Introduction: The anti-inflammatory metabolite adenosine addresses 4 receptors, which are differenzially expressed on cells. Recent studies indicate a role for specific adenosine receptors in liver diseases, including NASH, hepatic inflammation and fibrosis. Since it is unclear how far the A2B receptor modulates fibrogenesis, we investigated the selective A2B receptor antagonist MRS1754 in liver fibrosis progression and regression models. Methods: Mdr2(-/-) mice were injected intraperitoneally daily from week 6–10 of age either with vehicle (n=10), low dose (0,5mg/kg, n=10), or high dose MRS1754 (2mg/kg, n=10).…